Leerink Swann Weighs in on Shire PLC’s FY2016 Earnings (SHPG)
Shire PLC (NASDAQ:SHPG) – Leerink Swann dropped their FY2016 earnings estimates for Shire PLC in a research note issued to investors on Monday. Leerink Swann analyst J. Gerberry now anticipates that the firm will post earnings of $12.97 per share for the year, down from their prior estimate of $13.00. Leerink Swann has a “Outperform” rating and a $231.00 price objective on the stock.
A number of other equities research analysts have also weighed in on SHPG. Morgan Stanley reissued an “overweight” rating on shares of Shire PLC in a report on Friday, June 3rd. Piper Jaffray Cos. restated a “neutral” rating and set a $174.00 target price on shares of Shire PLC in a research report on Friday, July 15th. Citigroup Inc. restated a “buy” rating on shares of Shire PLC in a research report on Wednesday, August 3rd. Jefferies Group boosted their target price on shares of Shire PLC from $223.00 to $262.00 and gave the company a “buy” rating in a research report on Friday, June 3rd. Finally, Royal Bank Of Canada restated an “outperform” rating on shares of Shire PLC in a research report on Wednesday, June 15th. Five analysts have rated the stock with a hold rating and twenty-two have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $230.67.
Shire PLC (NASDAQ:SHPG) opened at 200.22 on Tuesday. Shire PLC has a 12 month low of $147.60 and a 12 month high of $231.32. The stock has a market cap of $59.64 billion, a price-to-earnings ratio of 41.61 and a beta of 1.11. The stock’s 50 day moving average price is $196.32 and its 200-day moving average price is $185.34.
Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.03 by $0.35. The firm earned $2.43 million during the quarter, compared to analyst estimates of $2.28 billion. Shire PLC had a return on equity of 17.70% and a net margin of 13.19%. The business’s quarterly revenue was up 55.9% compared to the same quarter last year. During the same quarter last year, the business posted $2.63 earnings per share.
Hedge funds have recently bought and sold shares of the stock. Jennison Associates LLC boosted its stake in Shire PLC by 13.2% in the second quarter. Jennison Associates LLC now owns 8,294,030 shares of the biopharmaceutical company’s stock valued at $1,526,765,000 after buying an additional 968,101 shares during the period. FMR LLC boosted its stake in Shire PLC by 86.7% in the second quarter. FMR LLC now owns 2,663,506 shares of the biopharmaceutical company’s stock valued at $490,297,000 after buying an additional 1,237,100 shares during the period. Lone Pine Capital LLC purchased a new stake in Shire PLC during the second quarter valued at $465,566,000. Capital World Investors purchased a new stake in Shire PLC during the second quarter valued at $285,568,000. Finally, Vanguard Group Inc. purchased a new stake in Shire PLC during the second quarter valued at $278,421,000. 24.26% of the stock is owned by institutional investors and hedge funds.
The company also recently declared a dividend, which will be paid on Friday, October 7th. Stockholders of record on Friday, September 9th will be paid a $0.139 dividend. The ex-dividend date is Wednesday, September 7th. Shire PLC’s dividend payout ratio (DPR) is 15.63%.
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.